India, July 13 -- Clinuvel Pharmaceuticals Limited (CUV.AX), a biopharmaceutical company, on Monday reported receiving a Notice of Compliance (NOC) from Health Canada for the drug SCENESSE for treating phototoxicity in patients of erythropoietic protoporphyria.
The granting of a NOC essentially clears the drug for marketing in Canada, indicating its compliance with Sections C.08.002 and C.08.005 of the Canadian Food and Drug Regulations.
Erythropoietic protoporphyria (EPP) is a rare metabolic disorder that causes debilitating phototoxic reactions and burns on exposure to the sun. The condition is rare, affecting about 5,000-10,000 people worldwide.
SCENESSE contains the peptide afamelanotide, an analogue of a naturally occurring hormone ...